Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  The Lancet

• Publication date

  2002-03-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0140-6736(02)07873-XPMID 11888582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase*

  2001cited by this paper
• Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses: Hsp60-mediated activation of cytotoxic T cells.

  2001cited by this paper
• Haplotype tagging for the identification of common disease genes

  2001cited by this paper
• High-resolution haplotype structure in the human genome

  2001cited by this paper
• Metabolic activation in drug allergies.

  2001cited by this paper
• TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients

  2001cited by this paper
• Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

  2001cited by this paper
• Mitochondrial toxicity and HIV therapy

  2001cited by this paper
• Hypersensitivity Related to Abacavir in Two Members of a Family

  2001cited by this paper
• Localization of central MHC genes influencing type I diabetes.

  2001cited by this paper
• Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4+ T Cells from Allergic Individuals1

  2000cited by this paper
• Abacavir rechallenge has to be avoided in case of hypersensitivity reaction.

  1999cited by this paper
• The role of heat shock proteins in the stimulation of an immune response.

  1998cited by this paper
• HLA-restricted , Processing-and Metabolism-independent Pathway of Drug Recognition by Human ab T Lymphocytes

  1998cited by this paper
• HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes.

  1998cited by this paper
• Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian.

  1997cited by this paper
• Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

  1997cited by this paper
• HLA and disease associations: detecting the strongest association.

  1994cited by this paper
• Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product.

  1992cited by this paper
• 5 Studies of MHC haplotypes by pulsed field gel electrophoresis

  1991cited by this paper
• Genetics of diabetes. Studies of MHC haplotypes by pulsed field gel electrophoresis.

  1991cited by this paper
• Disease Associations with Complotypes, Supratypes and Haplotypes

  1983cited by this paper
• Ankylosing spondylitis and HL-A 27.

  1973cited by this paper

• Genetic Variants Associated with Non-Steroidal Anti-Inflammatory Drug-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

  2026cites this paper
• Prediction of KIR3DL1 and human leukocyte antigen binding

  2025cites this paper
• Molecular docking to investigate HLA-associated idiosyncratic drug reactions

  2025cites this paper
• Pharmacogenetics: Opportunities for the All of Us Research Program and Other Large Data Sets to Advance the Field.

  2025cites this paper
• Distribution of CCR5-Δ32 and HLA-B*57:01 alleles in HIV-seropositive and HIV-exposed seronegative Peruvian individuals

  2025cites this paper
• Two-Dimensional Polymerase Chain Reaction for Identifying the HLA Alleles Associated with Adverse Drug Reactions.

  2025cites this paper
• Drug hypersensitivity reactions in children in clinical practice: A WAO Statement

  2025cites this paper
• Integrative Genomic and Immune Repertoire Profiling Identifies Clonal Signatures Linked to Antithyroid Drug-Induced Agranulocytosis

  2025cites this paper
• Preventing adverse drug reactions and more: current clinical use of pharmacogenetic testing

  2025cites this paper
• Comparison of different methods for the detection of HLA-B* 57:01 allele in people living with HIV in Eastern Uttar Pradesh, India

  2025cites this paper
• Enhancing clinical research with pharmacogenomics: a practical perspective.

  2025cites this paper
• A comprehensive update on the human leukocyte antigen and idiosyncratic adverse drug reactions

  2025cites this paper
• A review of the immunogenetics of Stevens-Johnson syndrome and toxic epidermal necrolysis

  2025cites this paper
• Differential Alloreactivity: Lessons Learned From a Singular HLA Locus

  2025cites this paper
• Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T-Cell Enhancement in Immunocompetent HLA-Transgenic Mice.

  2025cites this paper
• A privacy-preserving HLA imputation method with homomorphic encryption

  2025cites this paper
• Embedding Pharmacogenetics Into Clinical Practice to Improve Patient Outcomes

  2025cites this paper
• Genetic polymorphism contributes to efficacy and adverse reactions of tenofovir combination lamivudine-based highly active antiretroviral therapy in HIV-infected patients.

  2025cites this paper
• Pharmacogenetic biomarkers associated with risk of developing severe drug eruptions and clinical implementation of HLA genetic testing.

  2025cites this paper
• Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions.

  2024cites this paper
• Drug Allergy Mimics.

  2024cites this paper
• Endogamy and high prevalence of deleterious mutations in India: evidence from strong founder events

  2024cites this paper
• Frequencies of HLA-B alleles in Indonesian Malay Ethnic

  2024cites this paper
• The influence of single nucleotide polymorphisms on the therapeutic effect of antiretroviral drugs

  2024cites this paper
• Evidence for immune activation in pathogenesis of the HLA class II associated disease, podoconiosis

  2024cites this paper
• HLA-B allele frequencies and implications for pharmacogenetics in the Kuwaiti population

  2024cites this paper
• Pathological changes in various organs in HLA-B*57:01 transgenic mice with abacavir-induced skin eruption

  2024cites this paper
• Stevens–Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management

  2024cites this paper
• Biobanking with genetics shapes precision medicine and global health

  2024cites this paper
• Variation within the non-coding genome influences genetic and epigenetic regulation of the human leukocyte antigen genes

  2024cites this paper
• HLA-DPB1*05:01 and HLA-A*11:01 Is Associated with Adverse Drug Reactions to Isoniazid and Rifampin for Treatment of Latent Tuberculosis Infection in South Korea

  2024cites this paper
• Severe cutaneous adverse reactions

  2024cites this paper
• Risk factors for drug hypersensitivity reactions in children

  2024cites this paper
• Implementing pharmacogenomic testing in Australian general practice: an exploratory qualitative study

  2024cites this paper
• HLA-Related Drug Hypersensitivity Reactions

  2024cites this paper
• HLA-B*57:01-dependent intracellular stress in keratinocytes triggers dermal hypersensitivity reactions to abacavir

  2024cites this paper
• Exploring the preparedness of hospital pharmacists practising in Southwest London for implementing pharmacogenomics testing

  2024cites this paper
• Systemic and skin-limited delayed-type drug hypersensitivity reactions associate with distinct resident and recruited T cell subsets

  2024cites this paper
• Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis

  2024cites this paper
• An Overview on Adverse Drug Reactions (ADR) And Its Biomarkers

  2023cites this paper
• A Survey of the UK Pharmacy Profession’s Educational Needs on Pharmacogenomics

  2023cites this paper
• Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions

  2023cites this paper
• HLA-B*57:01 typing in a Malaysian cohort: implications of abacavir hypersensitivity in people living with HIV.

  2023cites this paper
• Allergic and other adverse reactions to drugs used in anesthesia and surgery

  2023cites this paper
• Dapsone hypersensitivity syndrome

  2023cites this paper
• Red hair and pain sensitivity: insights into genomics of pain?

  2023cites this paper
• Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.

  2023cites this paper
• Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators

  2023cites this paper
• Updates on HIV and Kidney Disease

  2023cites this paper
• The Safety and Accuracy of Drug Patch Testing in Delayed Hypersensitivity Reactions

  2023cites this paper
• Pharmacogenomics: current status and future perspectives

  2023cites this paper
• New insights into the diagnosis and management of Stevens–Johnson syndrome and toxic epidermal necrolysis

  2023cites this paper
• HLA-B*57:01/Carbamazepine-10,11-Epoxide Association Triggers Upregulation of the NFκB and JAK/STAT Pathways

  2023cites this paper
• Activation of human CD8+ T-cells with nitroso dapsone-modified HLA-B*13:01-binding peptides

  2023cites this paper
• The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population.

  2023cites this paper
• Prevalence of the HLA-B*5701 Allele and Abacavir Hypersensitivity in Saudi HIV Patients: A Multicenter Study

  2023cites this paper
• Pharmacogenomics and adverse effects of anti‐infective drugs in children

  2023cites this paper
• Genotypic and Phenotypic Characteristics of Co-Trimoxazole-Induced Cutaneous Adverse Reactions

  2023cites this paper
• Population genetics and external proficiency testing for HLA disease associations

  2023cites this paper
• Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review

  2023cites this paper
• Cutaneous adverse drug reactions.

  2023cites this paper
• Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System

  2022cites this paper
• Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis

  2022cites this paper
• Unravelling the Proteomics of HLA-B*57:01+ Antigen Presenting Cells during Abacavir Medication

  2022cites this paper
• Genetic Predisposition and the Variable Course of Infectious Diseases.

  2022cites this paper
• Drug-Induced Hypersensitivity Syndrome (DIHS)/ Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

  2022cites this paper
• A review of hypersensitivity methods to detect immune responses to SARS-CoV-2

  2022cites this paper
• Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis

  2022cites this paper
• Biochemical mechanisms of drug toxicity

  2022cites this paper
• The Immunogenetics of Cutaneous Drug Reactions.

  2022cites this paper
• Reacción a fármacos con eosinofilia y síntomas sistémicos (DRESS)

  2022cites this paper
• Pathophysiology of drug hypersensitivity

  2022cites this paper
• Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions

  2022cites this paper
• Association of Human Leukocyte Antigen Alleles and Hypersensitivity of Efavirenz/Nevirapine in HIV-Infected Chinese Patients

  2022cites this paper
• Skin Testing as a Biomarker in Drug Allergy.

  2022cites this paper
• Hypersensitivity reactions to small molecule drugs

  2022cites this paper
• The association of CD4 lymphocyte count with drug hypersensitivity reaction to highly active antiretroviral therapy, trimethoprim sulfamethoxazole, and antitubercular agents in human immunodeficiency virus patients

  2022cites this paper
• Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity

  2022cites this paper
• A low‐cost, sensitive and specific PCR‐based tool for rapid clinical detection of HLA‐B*35 alleles associated with delayed drug hypersensitivity reactions

  2022cites this paper
• Genetic markers of drug hypersensitivity in pediatrics: current state and promise

  2022cites this paper
• Integrating pharmacogenomics into clinical trials of hearing disorders.

  2022cites this paper
• Atopy as Immune Dysregulation: Offender Genes and Targets.

  2022cites this paper
• Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy

  2022cites this paper
• Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)—Readdressing the DReSS

  2022cites this paper
• Pharmacogenomic mechanisms of drug toxicity

  2022cites this paper
• Immunopharmaco-genomics: future of clinical medicine

  2022cites this paper
• An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice

  2022cites this paper
• Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics

  2022cites this paper
• Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity.

  2022cites this paper
• Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons.

  2022cites this paper
• Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in Thailand

  2022cites this paper
• Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance

  2022cites this paper
• Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.

  2022cites this paper
• Unconventional modes of peptide–HLA-I presentation change the rules of TCR engagement

  2022cites this paper
• Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects

  2022cites this paper
• Evidence of Biological Mechanisms and Health Predictions: An Insight into Clinical Reasoning

  2022cites this paper
• Advances in the Pathomechanisms of Delayed Drug Hypersensitivity.

  2022cites this paper
• Pharmacogenomics of Drug Hypersensitivity: Technology and Translation.

  2022cites this paper
• From pharmacogenetics to pharmaco-omics: Milestones and future directions

  2022cites this paper
• HLA-B*57:01 Complexed to a CD8 T-Cell Epitope from the HSV-2 ICP22 Protein Binds NK and T Cells through KIR3DL1

  2022influential citation